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EGF = epidermal growth factor; EGFR = epidermal-growth-factor receptor, erbB1; ERK = extracellular signal-regulated kinase; MAPK = mitogen-
activated protein kinase; MMTV = mouse mammary tumour virus; sFRP-1 = secreted Frizzled-related protein-1; TGF-α = transforming growth factor α.
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Introduction
The Wnt family of secreted growth factors plays key roles
in directing cell patterning both during development and in
adult tissues. Consequently, it is not surprising that sig-
nalling pathways downstream of Wnts have been impli-
cated in oncogenesis. While Wnts can also signal through
other pathways, to date the majority of investigation into
the potential role of Wnt signalling in the development of
cancer has focused on the Wnt/β-catenin pathway [1,2].
In this pathway, Wnts activate β-catenin signalling and
consequently modulate the expression of specific target
genes that regulate cell proliferation, apoptosis, and cell
fate [1,2]. The recent publication by Civenni and col-
leagues [3] demonstrating that Wnt overexpression in
mammary epithelial cells also activates signalling via the
epidermal-growth-factor receptor (EGFR; erbB1) points to
a further potential mechanism that may contribute to the
oncogenic potential of Wnts in the mammary gland.
Wnt signalling and mammary oncogenesis
Several Wnts are regulated during mammary development
[4] and Wnt-4 has been identified as a progesterone
target essential for lobuloalveolar development during
pregnancy [5]. Wnt-1 and -3 were first identified as poten-
tial mammary oncogenes because of their frequent activa-
tion by insertion of the mouse mammary tumour virus
(MMTV) [6,7]. Subsequent experiments showed that
Wnt-1 and Wnt-3A, but not all Wnt proteins, were highly
transforming for mammary epithelial cells in vitro [8], and
that Wnt-1 is overexpressed in breast cancer [9]. Several
oncogenic events that cooperate with Wnt overexpression
in experimental models of mammary oncogenesis have
been identified, including inactivation of p53 and activa-
tion of various fibroblast growth factor genes [10]. Evi-
dence suggesting that Wnt signalling through β-catenin is
the primary pathway for Wnt-mediated oncogenesis in the
mammary gland includes the similarities between the
effects of overexpression of activated β-catenin and Wnts
[11,12], although additional effectors are also likely to be
involved [12]. The downstream effectors of β-catenin
include the cell cycle regulatory molecules c-Myc and
cyclin D1, both well known mammary oncogenes that are
overexpressed in Wnt- or β-catenin-induced mouse
mammary tumours [11,12].
Commentary
Wnt signalling via the epidermal growth factor receptor: 
a role in breast cancer?
Elizabeth A Musgrove
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
Corresponding author: Elizabeth A Musgrove (e.musgrove@garvan.org.au)
Published: 24 October 2003
Breast Cancer Res 2004, 6:65-68 (DOI 10.1186/bcr737)
© 2004 BioMed Central Ltd (Print ISSN 1465-5411; Online ISSN 1465-542X)
Abstract
Recent data have suggested the epidermal-growth-factor receptor (EGFR) as a point of convergence
for several different classes of receptor. Civenni and colleagues have now demonstrated crosstalk
between Wnt signalling and the EGFR, showing that in breast epithelial cells Wnts activate
downstream targets of the EGFR, including cyclin D1. Given the role of members of these pathways in
the aetiology of breast cancer and as markers of outcome and potential therapeutic targets in breast
cancer, this observation has a number of potential implications important for both the basic biology of
breast cancer and the clinical management of the disease.
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Crosstalk between Wnt and erbB signalling
Links between the erbB family of receptor tyrosine kinases
and Wnt signalling were suggested by the observation
that Wnt-1 and Wnt-3 were commonly overexpressed
when the latency of mammary tumours induced by overex-
pression of the EGFR ligand TGF-α was reduced by infec-
tion with MMTV [13]. Subsequent work indicated that this
could be mediated, at least in part, by direct interaction
between β-catenin and EGFR/erbB2 heterodimers [14].
The identification by Civenni and colleagues [3] of a
further mechanism linking these two key signalling path-
ways has potentially major implications because of evi-
dence suggesting they are involved in the aetiology of
breast cancer. For example, the EGFR is overexpressed in
a significant fraction of breast cancers and appears to
confer a poor prognosis, at least in the subgroup of
patients that are negative for estrogen receptor [15].
Overexpression of Wnt-1 and Wnt-5a in HC11 mammary
epithelial cells or treatment with conditioned medium from
cells overexpressing these Wnts activated β-catenin, as
expected [3]. Surprisingly, however, these treatments also
stimulated EGFR tyrosine phosphorylation and activation of
extracellular signal-regulated kinase (ERK)1/2 activation,
events more usually associated with treatment with erbB
ligands [3]. Inhibition of EGFR kinase activity or addition of
secreted Frizzled-related protein-1 (sFRP-1), which com-
petes with Wnts for Frizzled receptors, both prevented this
effect; this observation is consistent with the conclusion
that Wnt-1 and Wnt-5A activated mitogen-activated
protein kinase (MAPK) signalling by EGFR. TGF-α and
other EGFR ligands were not induced by Wnt-1 or Wnt-5a,
but addition of metalloproteinase inhibitors blocked the
stimulation of EGFR and ERK phosphorylation. Thus, Wnt
activation of EGFR is apparently mediated by an increase
in the availability of EGFR ligands, for example by cleavage
from an inactive precursor molecule.
Ullrich and colleagues have implicated metalloproteinase
cleavage of the erbB ligands heparin-binding epidermal
growth factor (HB-EGF) and amphiregulin in EGFR sig-
nalling following G-protein-coupled receptor activation
[16,17]. The Frizzled receptors through which Wnts act
are 7-transmembrane domain receptors that are struc-
turally related to other families of G-protein-coupled
receptor, and consequently these observations have paral-
lels with those of Civenni and colleagues. In the series of
experiments by the latter authors, heparin-binding epider-
mal growth factor was expressed at higher levels than
other erbB ligands, leading the authors to conclude that it
is a likely candidate for mediating Wnt transactivation of
the EGFR [3]. However, previous studies indicate that
known erbB ligands commonly cause phosphorylation of
multiple receptors [18], whereas Wnt-induced phosphory-
lation of erbB2 and erbB3 were not observed [3]. It will be
interesting to investigate further the erbB ligand mediating
Wnt signalling and identify the particular metallopro-
teinase involved in its activation. Regardless of the spe-
cific ligand involved, the activation of only EGFR and not
other erbB receptors has implications for the conse-
quences of activation of this pathway by Wnt signalling,
since the erbB receptors preferentially activate different
combinations of signalling molecules and display different
oncogenic potencies [15]. The EGFR homodimer trans-
duces a relatively weak mitogenic stimulus and requires
the additional presence of ligand for transformation [15].
In contrast, erbB2/erbB3 heterodimers have potent mito-
genic and transforming activity [15].
Can the results obtained by Civenni and colleagues using
mammary epithelial cells in culture be translated to normal
mammary epithelium in vivo? The EGFR is essential for
murine mammary development, and EGF and other
ligands are potent inducers of ductal growth [19], but
EGF does not stimulate lobuloalveolar differentiation [20].
In contrast, expression of Wnt-1 and other Wnt/β-catenin
pathway genes stimulates lobuloalveolar development and
differentiation [4,11,12,21,22], producing a mammary
structure that is morphologically distinct from that arising
upon overexpression of EGFR [23]. Similarly, tumours
arising from activation of the erbB and Wnt pathways in
transgenic mice display distinct pathologies [24], although
it should be noted that the erbB receptor used in these
experiments was erbB2 rather than the EGFR. Further
experimentation will be necessary to determine the relative
balance between Wnt signalling via β-catenin and the
EGFR in various model systems. Again, since various erbB
ligand and receptor combinations have distinct roles in
mammary development [19], the precise erbB ligands and
receptors involved in Wnt signalling will also have implica-
tions for the role of Wnt–erbB crosstalk in mammary
development and oncogenesis.
Downstream effectors: cyclin D1
Cyclin D1 is a central component of regulation of breast
cancer cell proliferation and is frequently overexpressed in
breast cancer [25]. It is a target for Wnt signalling and
many other mitogenic signalling pathways, including those
downstream of steroid hormones and receptor tyrosine
kinases [25]. Civenni and colleagues show that Wnt
expression in HC11 cells or treatment with conditioned
medium from cells expressing Wnt-1 or -5A increases
expression of cyclin D1 and that this can be reversed by
inhibition of EGFR kinase activity or in the presence of
metalloproteinase inhibitors [3]. Thus, although in breast
cancers increased cyclin D1 expression is correlated with
the presence of nuclear or cytoplasmic (potentially active)
β-catenin [26], cyclin D1 induction via the EGFR predomi-
nates over its induction via β-catenin in these experiments.
Cyclin D1 is a weak mammary oncogene, as indicated by
the long latency of tumours arising in MMTV-cyclin D167
transgenic mice [27]. While induction of cyclin D1 is thus
a potential contributor to Wnt- and EGFR-mediated onco-
genesis, the increased proliferation resulting from
increased cyclin D1 expression is only one component of
the oncogenic process [28]. Cyclin D1 is essential for
mitogenic signalling through the EGFR in breast cancer
cells [29]. However, although cyclin D1 is acknowledged
as a critical target for Wnt signalling, it is not essential for
Wnt-1-mediated mammary tumorigenesis [30], raising the
possibility that Wnt activation of processes other than pro-
liferation may be central to its oncogenic role. An alterna-
tive explanation is that other, related molecules may
compensate for the absence of cyclin D1, thereby permit-
ting proliferation. Consistent with that idea, cyclin D2
expression is increased in mammary tumours arising in
MMTV-Wnt-1 mice [30], and in HC11 cells expressing
Wnt-1 (but not Wnt-5A) [3]. The latter response is intrigu-
ing in the light of the previous observation that Wnt-5A
failed to induce transformation under conditions where
Wnt-1 was highly transforming [8]. The mechanisms for a
Wnt-mediated increase in cyclin D2 in mammary epithelial
cells are unknown, but in some cell types the bicoid-
related transcription factor Pitx2 is rapidly induced by the
Wnt/β-catenin pathway and serves as a competence
factor that is necessary for cyclin D2 gene induction [31].
The restricted pattern of Pitx2 expression suggests that
this mechanism will be tissue-specific, but as the authors
point out, it may serve as a prototype for mechanisms
operating in other tissues.
Conclusion
The finding that Wnts activate erbB signalling in addition
to stimulating the prototypic Wnt/β-catenin signalling
pathway is provocative, revealing a new level of regulation
by members of the Wnt family and providing further
impetus for increased interest in these and other develop-
mental pathways in breast cancer. One question raised by
these studies is the relation between the expression pat-
terns of Wnts, the erbB ligands potentially mediating their
effects, and the metalloproteinases necessary for Wnt-
mediated activation of EGFR signalling in breast cancer,
and whether any relations identified are correlated with
outcome in breast cancer. These findings also emphasise
the interconnected nature of many signalling pathways in
breast cancer: crosstalk between Wnt and EGFR sig-
nalling is one example, but another example currently
under intense investigation is the emerging link between
steroid receptor and receptor tyrosine kinase signalling. In
both cases, better understanding of these pathways is
likely to have implications beyond the biology of breast
cancer, by identifying potential new markers of disease
outcome and therapeutic targets. As one example, the
ability of sFRP-1, which is down-regulated in a proportion
of breast cancers [9,32], to inhibit Wnt activation of EGFR
signalling suggests that therapies aimed at increasing
sFRP levels or activity may be effective.
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